SUNNYVALE, Calif., Sept. 17, 2019 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announces that The Lancet
Oncology, a high impact and leading global peer-reviewed
oncology journal, has published patient- and clinician-reported
outcomes data from the PACE — Prostate Advances in Comparative
Evidence — trial in its most recent issue. While further
investigation is planned, data reported in the journal indicate
that the level of grade 2 or higher acute genitourinary toxicity in
the stereotactic body radiation therapy (SBRT) arm of the trial is
lower for patients treated with the Accuray CyberKnife®
System than it is for patients treated on a conventional linear
accelerator.
SBRT involves the delivery of very high doses of
externally-administered radiation over a small number of treatment
sessions, offering convenience for patients, compared to
conventional radiation therapy which requires a substantially
longer course of treatment. SBRT is cost-effective for healthcare
providers and payers, and also increases patient satisfaction by
reducing scheduling inconvenience versus conventional radiation
treatments.
In the PACE trial, SBRT was delivered in five sessions while
conventional radiation therapy was delivered in 20 or 39 sessions.
Both the patient- and clinician-reported toxicity data demonstrate
that despite the high dose delivered to the prostate, use of SBRT
and conventional radiation therapy resulted in comparable rates of
acute gastrointestinal and genitourinary toxicity.
Chief Investigator Dr Nicholas van As, Consultant Clinical
Oncologist at The Royal Marsden NHS Foundation Trust, and Reader at
The Institute of Cancer Research, London, said: "At The Royal Marsden and the
ICR we are focused on developing smarter, better and kinder
treatments for patients across the UK and internationally.
Developments in radiotherapy such as SBRT mean we can target tumors
much more effectively. It is reassuring to see from this trial that
SBRT does not significantly impact patients' quality of life in the
short term, compared with the current standard of care. Using SBRT
to deliver this treatment would mean that patients could be spared
numerous visits to hospital, allowing them to get back to their
lives sooner."
The prostate gland can move unpredictably — as much as 10 mm in
as little as 30 seconds — throughout the course of treatment
because of normal patient bodily functions. This makes it
critically important to be able to track, detect and correct for
all types of motion. The CyberKnife Treatment Delivery System,
designed to deliver SBRT, is the only radiotherapy device that can
maintain sub-millimetric accuracy with continual imaging and
automatic beam delivery corrections, including rotation, throughout
treatment delivery, making it easier for clinicians to effectively
treat patients while minimizing dose to healthy tissue.
"The patient-reported outcomes, when viewed alongside those of
the participating clinicians, provide compelling rationale for
treating prostate cancer patients with SBRT, an effective and much
more convenient option for patients," said Birgit Fleurent, Chief Marketing Officer of
Accuray. "With more than 15 years of expertise and more than 100
peer-reviewed articles, there is robust clinical data supporting
the safety and efficacy of CyberKnife SBRT for the treatment of
patients with low- and intermediate-risk prostate cancer. And now,
with the Accuray Precision® Treatment Planning System
and the CyberKnife VOLO™ Optimizer, clinicians are able to
significantly reduce both the time to create high quality treatment
plans and the time to deliver patient treatments."
About the PACE-B Trial
PACE-B, an international phase 3 randomized controlled trial
comparing stereotactic body radiotherapy to conventionally
fractionated or moderately hypofractionated external beam
radiotherapy (CFMHRT) for localized prostate cancer, represents one
arm of a two-part trial. Further data on this arm, as well as the
second arm comparing hypofractionated SBRT to prostatectomy, will
be shared when available. Out of the 874 patients enrolled by 38
institutions, 845 patients were analyzed; 431 receiving SBRT and
414 CFMHRT. Men who were unsuitable for surgery or preferred
treatment with external beam radiation therapy were eligible to
participate. The trial evaluated the treatment regimens across
multiple effectiveness and safety metrics.
About the CyberKnife® System
The CyberKnife System is the only robotic radiosurgery system that
offers highly precise, non-surgical treatment for tumors and
lesions anywhere in the body—including the brain, breast, kidney,
liver, lung, pancreas, prostate and spine. The CyberKnife System
tracks and automatically adjusts for tumor or patient movement
during treatment, delivering the radiation dose directly to the
target with sub-millimeter precision. Synchrony® motion
tracking and correction technology expands on the CyberKnife
System's unique motion synchronization capabilities to provide
additional precision when treating tumors that move with
respiration. The high level of accuracy in dose delivery made
possible by the system gives clinical teams the confidence to
deliver state-of-the-art treatments for a wide range of cancers and
functional disorders, without sacrificing patients' quality of
life.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please
visit www.accuray.com or follow us
on Facebook, LinkedIn, Twitter and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to the benefits of SBRT
relative to conventional radiation treatments, clinical
applications, clinical results, patient experiences and outcomes,
and Accuray's leadership position in radiation oncology innovation
and technologies. These forward-looking statements involve risks
and uncertainties. If any of these risks or uncertainties
materialize, or if any of the company's assumptions prove
incorrect, actual results could differ materially from the results
expressed or implied by these forward-looking statements. These
risks and uncertainties include, but are not limited to, the
absence of future articles or publications that diminish or
questioning the efficacy and safety of SBRT, the company's ability
to achieve widespread market acceptance of its products, including
new product offerings, the company's ability to develop new
products or enhance existing products to meet customers' needs,
delays in the development or release of new offerings and such
other risks identified under the heading "Risk Factors" in the
company's annual report on Form 10-K, filed with the Securities and
Exchange Commission (the "SEC") on August
23, 2019, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future
events. The company assumes no obligation to update
forward-looking statements to reflect actual performance or
results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly, investors
should not put undue reliance on any forward-looking
statements.
Media
Contacts:
|
|
Beth
Kaplan
|
Jayme
Maniatis
|
Public Relations
Director, Accuray
|
MSLGROUP
|
+1 (408)
789-4426
|
+1 (781)
684-6610
|
bkaplan@accuray.com
|
accuray@mslgroup.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/data-published-in-the-lancet-oncology-suggest-cyberknife-prostate-patients-experienced-lower-levels-of-acute-genitourinary-toxicity-grade-2-or-higher-than-patients-treated-on-a-conventional-linear-accelerator-300919972.html
SOURCE Accuray Incorporated